Company Description
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006.
AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | Jan 26, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 104 |
| CEO | Daniel Faga |
Contact Details
Address: 10770 Wateridge Circle, Suite 210 San Diego, California 92121-5801 United States | |
| Phone | 858 362 6295 |
| Website | anaptysbio.com |
Stock Details
| Ticker Symbol | ANAB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001370053 |
| CUSIP Number | 032724106 |
| ISIN Number | US0327241065 |
| Employer ID | 20-3828755 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel R. Faga | President, Chief Executive Officer and Director |
| Dennis M. Mulroy | Chief Financial Officer |
| Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D. | Chief Medical Officer |
| Eric J. Loumeau | Chief Legal Officer |
| Beth Mueller | Senior Vice President of Human Resources |
| Dr. Martin Dahl Ph.D. | Senior Vice President of Research |
| Benjamin Stone | Chief Business Officer |
| Monique Da Silva | Senior Vice President of Corporate Affairs |
| Priya Raina | Senior Vice President of Clinical Operations |
| Cailin Sibley FACR, M.D. | Senior Vice President of Translational Medicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | 10-K | Annual Report |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 11, 2026 | 144 | Filing |
| Feb 11, 2026 | SCHEDULE 13G/A | Filing |
| Jan 16, 2026 | SCHEDULE 13G/A | Filing |
| Jan 15, 2026 | 144 | Filing |
| Jan 9, 2026 | 144 | Filing |
| Jan 9, 2026 | 144 | Filing |
| Jan 9, 2026 | 144 | Filing |
| Jan 9, 2026 | 144 | Filing |